Wexford-based biopharmaceutical company Coeptis Inc. announced the formation of GEAR Therapeutics, a majority-owned ...

Scientists at the Wisconsin National Primate Research Center (WNPRC) and the Morgridge Institute for Research at the ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of ...

Stem cells from the patient's healthy eye transplanted into the injured eye successfully repairing previously "irreversible" ...

Overview: Initial test, a single-arm, open-label 1st-in-human proof-of-concept study in adults with distal radius fractures.

A new stem cell therapy is giving hope to patients with serious cornea injuries. This breakthrough treatment could revolutionize eye health.

Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

After hours: March 7 at 4:05:05 PM EST Loading Chart for IMTX ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

ORLANDO — A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy ...